SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Nov. 8, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Wednesday, November 15, 2023, at 8:30 a.m. GMT/ 3:30 a.m. ET in London.
David. R. Parkinson, President, and Chief Executive Officer; Peter Virsik, Chief Operating Officer; and David S. Wood, Chief Financial Officer, will host and participate in one-on-one meetings.
A live webcast of the Jefferies presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the event, the webcast will be archived on the ESSA website for 90 days.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com, and follow us on Twitter and LinkedIn.
ESSA Pharma, Inc.
Peter Virsik
Chief Operating Officer
778.331.0962
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors and Media:
Argot Partners
212.600.1902
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.85 |
Daily Change: | 0.09 5.11 |
Daily Volume: | 373,702 |
Market Cap: | US$82.080M |
September 13, 2024 September 11, 2024 August 05, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB